August 30, 2019
1 min read

Glenmark receives FDA approval for generic atopic dermatitis cream

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA has granted final approval for pimecrolimus cream 1%, a generic form of Elidel, according to an announcement from Glenmark Pharmaceuticals.

Sales of Elidel cream (pimecrolimus 1%, Bausch Health) for the 12-month period ending in July totaled approximately $198.8 million, according to IQVIA data in the announcement.

In light of this news, here are five recent Healio Dermatology headlines in atopic dermatitis research spanning gene variants, atrial fibrillation and biologic therapy.


Filaggrin gene loss-of-function variants differ by race in children with atopic dermatitis

Variant frequency in the filaggrin gene was strongly associated with race among pediatric patients with atopic dermatitis. Read more.


Moderate to severe atopic dermatitis may increase risk for atrial fibrillation

Patients with moderate to severe atopic dermatitis had a 20% increase in the long-term risk for atrial fibrillation although the absolute risk remains low, according to findings from a 35-year cohort study. Read more.


Baricitinib meets primary endpoint in adults with atopic dermatitis

Baricitinib met the primary endpoint in adults with moderate to severe atopic dermatitis in BREEZE-AD7, the third pivotal phase 3 trial of the BREEZE-AD program, which is expected to be completed later this year. Read more.


Long-term dupilumab treatment safe, effective for atopic dermatitis

Dupilumab showed consistent and sustained efficacy in an open-label extension study in adults previously enrolled in 12 parent studies assessing dupilumab in moderate to severe atopic dermatitis. Read more.


Dupixent shows positive results in children with severe atopic dermatitis

Children aged 6 to 11 years with severe atopic dermatitis assigned dupilumab and topical corticosteroids significantly improved in measures of overall disease severity, skin clearing, itching and health-related quality of life vs. topical corticosteroids alone in a phase 3 trial. Read more.